Tactiva Therapeutics operates as an immuno-oncology company. It is mainly engaged in developing cancer immunotherapy for potent cancer treatment using a dual T cell receptor approach. The Company utilizes cells of the CD4 T class to enhance the anti-tumor function of CD8 T cells, as well as exhibit a capacity to directly target the tumor cells.